RegulatoryOfficial

European Commission authorises Zealand Pharma's Zeydovio (glepaglutide) via centralised procedure

🇪🇺 European Commission (Union Register) · Thu 12 Nov 2026

Commission Decision (2026) 8239 of 12 November 2026 adds Zeydovio, held by Zealand Pharma A/S, to the Union Register of centrally authorised medicines.

The European Commission has granted a new marketing authorisation for Zeydovio, whose active substance is glepaglutide. The product is held by Zealand Pharma A/S.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Official source: European Commission (Union Register) ↗

Article written by VigiEye from the official source (European Commission (Union Register)). AI-assisted; check the source before acting.

More Regulatory All →